Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05223868 · ClinicalTrials.gov registry record · Phase 2
A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis
A Phase 2 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 255
- Enrollment target
NCT05223868 is a Phase 2 study that has completed, run by Janssen Research & Development. The registered enrollment target is 255 participants.
The verdict
NCT05223868, a Phase 2 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 255 participants
- Enrollment target
Study Summary
Th purpose of the study is to evaluate the dose response of JNJ-77242113 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
Interventions
- DRUG Placebo
- DRUG JNJ-77242113
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2022-02-03 |
| Est. Completion | 2022-12-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05223868
The ClinicalTrials.gov registry entry for NCT05223868 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05223868 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05223868 about?
NCT05223868 is a clinical study titled "A Study of JNJ-77242113 in Participants With Moderate-to-severe Plaque Psoriasis". Th purpose of the study is to evaluate the dose response of JNJ-77242113 in efficacy at Week 16 in participants with moderate-to-severe plaque psoriasis.
What is the current status of trial NCT05223868?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 255 participants. The study started on 2022-02-03. Estimated completion is 2022-12-15.
What interventions are being tested in trial NCT05223868?
The interventions under investigation include: Placebo (DRUG), JNJ-77242113 (DRUG).
Who is sponsoring clinical trial NCT05223868?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.